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Background: Médecins Sans Frontières (MSF) is one of the world’s leading humanitarian medical organizations. The
increased emphasis in MSF on research led to the creation of an ethics review board (ERB) in 2001. The ERB has
encouraged innovation in the review of proposals and the interaction between the ERB and the organization. This
has led to some of the advances in ethics governance described in this paper.
Discussion: We first update our previous work from 2009 describing ERB performance and then highlight five
innovative practices:
• A new framework to guide ethics review
• The introduction of a policy exempting a posteriori analysis of routinely collected data
• The preapproval of “emergency” protocols
• General ethical approval of “routine surveys”
• Evaluating the impact of approved studies
The new framework encourages a conversation about ethical issues, rather than imposing quasi-legalistic rules, is
more engaged with the specific MSF research context and gives greater prominence to certain values and
principles. Some of the innovations implemented by the ERB, such as review exemption or approval of generic
protocols, may run counter to many standard operating procedures. We argue that much standard practice in
research ethics review ought to be open to challenge and revision. Continued interaction between MSF researchers
and independent ERB members has allowed for progressive innovations based on a trustful and respectful
partnership between the ERB and the researchers. In the future, three areas merit particular attention. First, the
impact of the new framework should be assessed. Second, the impact of research needs to be defined more
precisely as a first step towards being meaningfully assessed, including changes of impact over time. Finally, the
dialogue between the MSF ERB and the ethics committees in the study countries should be enhanced.
Summary: We hope that the innovations in research ethics governance described may be relevant for other
organisations carrying out research in fragile contexts and for ethics committees reviewing such research.
Keywords: Research ethics, Humanitarian contexts, Framework for ethics review, Research impactBackground
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unless otherwise stated.are rooted in ethics [1]. Historically, research was not seen
as core to the mission of MSF. However, during its history,
MSF has constantly developed innovative protocols and
tools, in response to unmet field needs [2]. It now initiates,
sponsors or participates in numerous research projects in
multiple field sites. In 2013 alone, 253 research papers
were published [3]. The results of MSF research have had
substantial impact on global health policy and provide
benefits to populations served by MSF and elsewhere as
presented later in this paper. MSF has also shown leader-
ship in operational research initiatives in the humanitarianral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ingly integral to MSF activities, both in the field and in
global health advocacy. The increased emphasis on re-
search led to the creation of an ethics review board (ERB)
in 2001. From the outset independence of the ERB from
the organisation was perceived as essential. To avoid con-
flict of interest and ensure independence, ERB members
cannot have a working relationship with MSF during their
tenure. The ERB has now been in place for thirteen years.
The ERB’s dialogue with MSF has enhanced sensitivities
towards research ethics and lead to gradual improvements
in developing ethically sound proposals. The consistent
use of an ethics framework has helped in standardizing
the review process and guiding field research teams in ad-
dressing ethical issues. The way that the ERB functions
and the challenging ethical issues addressed by the ERB
since its inception have been described previously [5]. The
ERB strives to take a constructive approach to both
research proposals and the field of research ethics itself.
The ERB has encouraged innovation in both the review of
proposals and the interaction between the ERB and the
organization.
In the view of the ERB ethics review should not be
dogmatic and ought to be proportionate in terms of
benefit and harms. The ethics review procedure and its
stringency should be commensurate with the type of re-
search based on an approximate estimation of potential
harm (Figure 1).
This has led to some of the advances in ethics govern-
ance further described in this paper. Some of the inno-
vations implemented by the ERB may run counter to
standard operating procedures and guidance documents
that are utilized in various jurisdictions. We argue that
much standard practice in research ethics review ought
to be open to challenge and revision, and this irrespec-
tively of the actors and the context of the research.Figure 1 Proportionality of ethics review.Research ethics is a field that should not be regarded as
a set of rigid standards fixed for all time and in all con-
texts. Much of current research ethics practice lacks an
empirical basis, and many recommended standards are
based on historical practice. From our perspective,
research ethics and research ethics practices are capable
of being examined through research and a quality im-
provement approach. Any genuine ethics review requires
critical reflection and discussion, not the pedestrian
adoption of legalistic rules, and it should result in a
learning process for both the researchers and the re-
viewers. Fostering a spirit of innovation and evaluation
in research ethics practice demonstrates that research
ethics itself is an active and essential component of
global health research. In this paper we describe innova-
tions that we think challenge accepted practices and thus
hope to stimulate a more vigorous debate in this area,
beyond the realm of research carried out by MSF.
To contextualise our proposals for changes in research
ethics governance, we will first update our previous work
from 2009 [5] describing ERB performance and then
highlight five innovative practices:
 A new framework to guide ethics review
 The introduction of a policy exempting a posteriori
analysis of routinely collected data
 The preapproval of “emergency” protocols
 General ethical approval of “routine surveys”
 Evaluating the impact of approved studies
Discussion
ERB performance
Before describing the five areas of innovation, we will
briefly give an overview of ERB activities and perform-
ance focusing on the past four years. Since its inception,
the volume of ERB activity has increased considerably,
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248 research protocols were reviewed by the ERB be-
tween 2002 and 2013 with an almost ten-fold increase in
the number of protocols across that period (Figure 2).
Protocols are always submitted to the ERB and to the
Ethics Committees in the study country, and the ap-
proval from the local Ethics Committee is a fundamental
prerequisite to the ERB approval. In very rare instances,
the ERB may waive this request if, for example, no ethics
committee or national body able to play a similar func-
tion is available, or if it is justified not to collaborate
with the legal authorities, as this could be detrimental to
the population served by MSF (e.g. working in a conflict
zone with a population group persecuted by national
authorities).
In 2010–2011, 56 requests for review were received in
24 months. This increased to 72 requests during the
two-year period 2012–13, despite the fact that during
this time research based on a posteriori analyses of rou-
tinely collected clinical data was no longer submitted to
the ERB for review. Of this number 61 were expedited
reviews and 11 were full board reviewsa.
The Board is also evaluating the timeliness of its re-
views. An audit of proposals from 2010–2013 (four-year
period) demonstrated an average time to approval of
twelve weeks (Figure 3).
Figure 3 shows that, on average, the ERB needs more
time for doing the first review (time between MSF
request and finalizing ERB review) than researchers for
responding (time between ERB review and MSF reply) in
the case of expedited review. However, the ERB is faster
than the investigators in case of full review. Once a satis-
factory reply and revisions from the researchers are re-
ceived, approval is usually granted quickly. Overall the
procedure is faster for expedited review than for full re-
view. This is mainly due to the fact that proposals sub-
mitted for expedited review are judged to be of minimal
risk of harm, that study design is often less complex and
that a smaller number of reviewers is involved. Assessing
the timeline of the review procedure is a relevant indica-
tor of ERB performance and dispels the myth that theFigure 2 Reviews since ERB inception.ERB is responsible for a slow review process. Also, the
overall time to approval should not be seen as the “time
to getting a stamp”, but as a time of dialogue and critical
reflection on both sides. In addition, ERB timelines are
shortened in case of extraordinarily urgent situations
and turnaround can occur within a few days.
To further improve its decentralized and very reactive
way of functioning, a web-based platform was created
exclusively for the MSF ERB. This platform provides ac-
cess for ERB members to all routine communications,
active files and ERB archives including all past ERB
reviews, protocol amendments, research reports, ERB
decisions, relevant MSF or ERB policies.
In the rest of this paper we outline five different inno-
vations that have resulted in proportionate ethics review,
without compromising on the fundamental role of the
ERB.
A new framework to guide ethics review
A new framework to help guide ethics review was
adopted by MSF in November 2013. This replaced a
previous ethics framework that had been adapted from
the work of Emanuel et al. [6]. In this section we will ex-
plain both what is different about the new framework
and why the changes were made. However, we will begin
by explaining why a framework is necessary at all. What
is an ethics framework? What is its role? How does it
work?
An ethics framework can serve many purposes. First,
it seeks to articulate and make explicit the kinds of
values or other ethical considerations that are taken to
be of crucial importance in relation to the topic in hand,
in this case, the ethics of research conducted in the
course of humanitarian medicine. Any framework will
be the product of a particular time, influenced by the
knowledge and experience of those involved in produ-
cing it. Articulating the considerations that are held to
be relevant allows for transparent discussion, critique
and development of the framework over time in the light
of evolving situations. Second, and perhaps most crucially,
an ethics framework provides assistance to researchers
and others that evaluate and/or make decisions about the
ethics of research. This means that a framework will often
be an aid to research design and deliberation, not just a
theoretical expression of ideals. On this view, it ought to
be of use to members of the ethics board, but also of aid
to researchers and anyone else thinking about the relevant
issues (as the document is publicly available on the MSF
website [7]). Third, it is also important to recognise what
a framework does not do. It does not, for example, deter-
mine what should or should not be done. It is not a piece
of legal or quasi-legal regulation. Rather, its intent is
clearly expressed by the metaphor of ‘framing’; it aims to
‘frame’, or provide an outline or structure for a focused
Month 1 Month 2 Month 3 Month 4 Month 5
ERB ApprovalMSF reply
ERB approval
MSF reply
ERB review
ERB review
MSF request
ERB 39 days
MSF 28 days
ERB 19 days
ERB 47 days
MSF 61 days
ERB 25 days
Figure 3 Average time procedure for expedited review (in blue) and full review (in orange).
Table 1 An example of the ‘Benchmarks’ Linked to a
‘Principle’ in the old framework
Principle Benchmarks
Collaborative
Partnership
1) Engage in partnership with national and/or
international research institutions as relevant
and appropriate.
2) Collaborate with local and national researchers
and health policymakers to share responsibilities
for determining the importance of health problem,
assessing the value of the research, planning,
conducting, and overseeing the research, and
integrating the research into the health system.
3) Respect the community’s values, culture, traditions,
and social practices.
4) Involve the community in which the study takes
place (hereinafter referred to as “study community”)
through a consultative process in designing the
research, in its implementation (advice on problems
occurring during study, feedback of intermediate
results) and in assessing how research results may
be made beneficial.
5) Contribute to developing the capacity for researchers
and health policymakers to become full and equal
partners in the research enterprise.
6) Share fairly the financial and other rewards of the
research.
Schopper et al. BMC Medical Ethics  (2015) 16:10 Page 4 of 12and relevant discussion and eventual decision, not to
provide a list of necessary and absolute principles or
statements.
The original MSF ERB framework was based on the
work of Emanuel et al. This was used, because at the time
it was the most practically orientated of the various frame-
works, guidelines and documents available. It provided a
coherent summary of the issues that were central to dis-
cussions of research ethics, building upon the many docu-
ments then available [8-10]. The Emanuel framework
seemed to synthesize these diverse guidelines into some-
thing tangible. Despite its limitations briefly described
below, it provided a focus for both reviewers and re-
searchers. It is fair to say that the new ethics framework is
a development from the work of Emanuel et al., but it is
significantly different in a number of ways.
There were three main motivations for developing a
new framework. First, and perhaps most importantly,
the Emanuel framework actually provides little practical
guidance. It is more of a checklist of important consider-
ations than a framework that facilitates making ethical
judgments. For example, the framework is structured in
terms of a series of ethical ‘principles’ and related
‘benchmarks’. However, it is unclear what a benchmark
is. How do the different ‘benchmarks’ relate to each
other? What is the moral status of a benchmark? Is it an
ethical principle, a value or just a statement? What prac-
tical priority is to be given to each principle or bench-
mark? How do the different principles and benchmarks
relate to each other and what should we do if they
conflict? Is the presented order of the principles and
benchmarks important or not? For example, the old
framework’s first stated ‘principle’ is ‘Collaborative Part-
nership’, followed by ‘Social Value’ and then ‘Scientific
Validity’. In what sense are these supposed to be princi-
ples? They might be things that researchers and the ERB
are supposed to ‘take into account’, but how do they dothis? Is “Collaborative Partnership” the most important
‘principle’? Is that why it is first? Emanuel et al. [8] sug-
gest that their requirements are presented in chrono-
logical order, although the detail of the order could be
questioned. For example, why is a procedural require-
ment (independent review) in the list, and why does it
appear where it does? Why is informed consent prior to,
and separate from, respect for potential and enrolled
subjects? If we consider the ‘benchmarks’ the first thing
that is noticeable is that they are very didactic (Table 1).
The benchmarks state what should happen in a firm and
clear way. There is a mixture of useful advice about
engaging with local communities and researchers, although
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tical reasons e.g., because this is the best way to get the
study results? Or is it for ethical reasons? If so, it is unclear
what they might be, especially as ‘collaborative partnership’
is not an ethical principle. For example, you might expect
some possible commitment to ideas of respect, or equality
and justice. Second, the benchmarks are not always helpful.
For example, consider the benchmark: ‘Respect the com-
munity’s values, culture, traditions, and social practices’.
What does this mean? Does this relate to the kinds of
issues just mentioned, such as a commitment to equal
respect and value of persons? Are we to take it literally as a
general didactic statement? Is it a commitment to some
form of relativism? Are we to commit ourselves to engage
with and effectively endorse any existing injustices in the
population of study? If women have a marginalised role in
that society, should we ‘respect’ this? At the very least,
these are complex matters where the benchmarks often
fail to capture the nuances relevant to thinking about
ethics. Similar kinds of questions can be asked of many
other research ethics frameworks and guidelines, as it is
often left obscure how they are to be used as practical
tools [11,12].
Second, the academic literature and debates have pro-
liferated and developed over the last ten years, especially
in relation to post-research benefits for host populations.
Many of these discussions are of particular importance
for research conducted by MSF. MSF as a medical or-
ganisation is providing health care to vulnerable and
destitute populations and is devoting limited resources
to research with the sole aim of improving health care.
Third, there has been a growing awareness that the kind
of research conducted by MSF may not be well served
by traditional research ethics for several reasons: the
chosen method is only rarely one of a randomised
clinical trial of novel medicines (the model that has
dominated research ethics) and is more likely to use
retrospective analysis of previously collected clinical
data, surveys, needs assessment or case control methods;
the context for research is distinctive, in that much
research is conducted in contexts of disaster, conflict,
poverty, social exclusion and lack of access to care, dis-
rupted health systems or other difficult circumstances,
where there is great vulnerability and pressing humani-
tarian needs.
We believe that the new ethics framework [13] is an
improvement in a number of ways. First, the overall
structure of the framework is clearer. The issues are
now placed into three groups (Research Question and
Methodology; Respecting and Protecting Research Par-
ticipants and Communities; Implications and Implemen-
tation of the Research Findings) to reflect a logical
temporal order of things to consider before, during and
after the research has been conducted. Second, thisstructure and, in particular, the use of questions should
aid deliberation by anyone using the framework. For-
mulating the content of the framework in terms of
questions very deliberately ‘frames’ the discussion about
research ethics. It provides an open and flexible ap-
proach, rather than seeking to articulate a number of
general statements. Table 2 illustrates this by focusing
on the issue of informed consent.
The old framework sets out a set of commands as if
they were absolute rules that must be followed. The new
framework covers much of the same ground, but ap-
proaches the issues in a different spirit. It seeks to invite
researchers to justify their approach. It accepts that
sometimes it is inappropriate or impossible to gain a
fully informed consent from every individual. Help is
offered to the researcher, but the aim is to encourage a
conversation about ethical issues, rather than impose
quasi-legalistic rules. The questions help potential re-
searchers to see what the ERB wishes to see in a proto-
col and ethics application, but can also help researchers
come to understand ethical issues in more detail, and
how ethical issues are intertwined with methodological
issues. The use of open questions requires researchers to
engage with the framework and outline and defend how
they will address the relevant issues that they have iden-
tified. Ethics review is more of an active process, with
the researcher as a participant, rather than the victim of
an alien and abstract set of rules. Third, the new frame-
work is more engaged with the specific MSF research
context. This means that certain values/principles/issues
are given much greater prominence than they ever have
before. For example, it is now much clearer how meth-
odological and ethical issues interact and the obligations
that arise once research has been completed are much
more prominent and require greater attentionb.
The new framework has been implemented since
November 2013 and has been well received by MSF
researchers. It will be evaluated after 12 to 18 months’ use
from the researchers and the ERB’s perspective.
Exempting research based on a posteriori analysis of
routinely collected data from review
MSF collects a vast amount of data as part of its routine
clinical procedures. At a later stage these data may be
useful to evaluate programme outcomes, analyse predic-
tors of treatment outcomes, or assess factors influencing
programme or treatment effectiveness. As the number
of protocols aimed at generating this kind of data sub-
mitted to the ERB for review was steadily increasing, the
possibility of delegating ethical responsibility for this
type of study to the MSF medical directors under certain
conditions was discussed at a joint meeting of the ERB
and medical directors in June 2010. Primary consider-
ations concerned (1) how these data were collected and
Table 2 An example of the difference between the two frameworks: consent
Old framework New framework
1) Involve the study community in establishing appropriate
recruitment procedures and incentives for the participants.
(2.2) What are your plans for obtaining consent? A requirement to inform
participants is often seen as being an important way to show respect and
promote patient autonomy and welfare.
2) Ensure that consent procedures are acceptable within the
study community (may include supplementary community
and familial consent procedures).
a. What information ought to be provided? This will usually include the
following elements: the reasons for doing research, details about who is
doing the research, why the potential participant is being asked to be
involved, details about what any intervention might involve and any
on-going commitments of participation, details about anticipated risks
and benefits, the fact that participants are free to refuse or withdraw,
that any findings will be communicated back to the participants etc.
The information given should be proportionate to any risks, but this does
not mean that the higher the risk, the more information ought to be
provided. Sometimes, calling attention clearly to a common or
significant particular risk is more important than listing every possible
remote risk.
3) Disclose information in culturally and linguistically appropriate
formats. This implies that
• any information given during the informed consent process
must be pretested with people of a similar cultural and
educational background as potential study participants;
• the information provided on the consent form must be in
simple language, avoiding technical terms;
b. Providing information does not guarantee it has been understood. How
can information be provided at an appropriate linguistic level, without
jargon or technical terms, and appropriate to the local language
and culture?
• the consent form must be translated into the local language
and then back-translated into the “international” language used
to get a sense of the accuracy of the translation and correct
mistakes;
c. Should information be provided in oral and/or written form?
4) Ensure that participants fully comprehend the research
objectives and procedures:
d. How will the consent process be conducted? You may want to consider
issues such as: who will consent, where they will do so (is the place
appropriate to allow a confidential discussion), will a witness to the
consent be required, how much time will be offered to consider whether
to be involved? Prior engagement with communities can be a useful way
to ensure that the consent process meets local expectations and
sensitivities. How will the act of consent be recorded (e.g. signed and
witnessed document, thumb print etc.)?
• if needed, the person should get time to discuss the information
received with members of the community or family before
deciding on consent;
e. Alternative or additional consent procedures may need to be developed
where potential participants are minors, minor parents, or suffering from
short or long-term incapacities etc.
• in addition, community information or “schooling” on the research
to be done and on the purpose and process of seeking informed
consent will raise pre-enrolment awareness and thus help people
to decide if they want to participate in the study.
f. It should not be assumed that a long and complicated information sheet is
always necessary and in exceptional cases it may be justifiable not to seek
informed consent. Where researchers believe that this is appropriate, they
should be careful to providereasons for this in the protocol.
5) Obtain consent in culturally and linguistically appropriate formats.
6) Ensure that potential participants are free to refuse or withdraw
from the research at any stage without penalty..
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their health data. Collecting routine clinical data should
presumably follow universal ethical principles and thus
might be thought to require consent. The ERB thus en-
couraged MSF to establish a policy on routine collection
of data in clinical settings. The uses of such data may
carry a low risk of harm, informing each patient may be
difficult to implement and it is arguable that consent to
at least some uses is implicit in clinical care. It was thus
suggested that MSF consider a variety of ways of inform-
ing people about the possible uses of their data (e.g. well
displayed posters describing the potential uses of health
data collected in the clinic).
It was agreed that a posteriori analyses of routinely
collected clinical data do not require ERB review, if MSF
as an organization through the medical directors (whoare overseeing research) takes responsibility for address-
ing the ethical issues. The following seven criteria must
be fulfilled to qualify for exemption from ERB review:
1. Studies/articles are based on routinely-collected
programme and clinical data.
2. They are either descriptive or targeted evaluations.
3. Confidentiality is respected; no individual patient
identifiers are revealed.
4. Harm is minimal but acknowledged where relevant.
5. Potential benefits to both the programme and the
community are described. Since the goal is
publication, the relevance to a wider audience is
described.
6. Collaborative involvement and, if applicable,
authorship from a local medical or public health
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other NGO) is encouraged. If relevant and possible,
consultation with a body representing the
community is desirable.
7. If the decision for exemption from review is taken
by the medical directors, the MSF responsibility to
ensure that ethical requirements are met is similar
to reviewed projects. This exemption, in addition,
does not exempt MSF from compliance with
regulatory requirements in the country from where
the data originate. National or institutional ethical
review may still be required.
Consequently between June 2010 and December 2013,
127 protocols involving exclusively a posterior analysis
of routinely collected data were directly exempted from
review by the medical directors. In case of doubt proto-
cols are submitted to the ERB to ensure all criteria are
met. This was the case six times in 2013. In all instances
the ERB confirmed that exemption criteria were met.
The list of exempted studies is provided to the ERB at
the end of each calendar year. The ERB retains the right
to audit exempted studies to verify that exemption cri-
teria are respected.
Preapproval of ‘emergency’ protocols
There is considerable uncertainty about optimal inter-
vention in many dimensions of humanitarian medicine.
Humanitarian interventions, as already noted, occur in
an unpredictable manner and in uncertain contexts.
Often the response must be implemented quickly and
not according to the time table of meetings for estab-
lished research ethics boards.
The need for rapid, yet robust, research ethics review
has been noted in the literature. Experiences with SARS
and pandemic influenza have demonstrated that existing
research ethics structures are poorly tailored for rapid
assessment and feedback in a sufficiently timely manner
and may hinder legitimate research with potential benefits
[14]. Recommendations for addressing these deficiencies
have been tabled [15].
MSF frequently carries out research in emergency situ-
ations which do not allow sufficient time for prior ethics
review. In a paper on MSF emergency research “external
ethical review” is briefly mentioned with no indication if
and how it is implemented [16]. The ERB has repeatedly
been asked to conduct a posteriori reviews of emergency
research in form of draft papers prior to publication. As
emergency research may have serious implications for
research participants, the issue of ethics review was
revisited.
One recommendation that was adopted and passed by
the MSF ERB was for pre-approval of generic protocols.
Infectious disease outbreaks are a good example of thetype of situation where such pre-approval can take place.
There are often well structured research questions that
are supported by the evidence as being a priority for
answering through rigorous research. Protocols have been
developed, but there is uncertainty about where the next
outbreak will occur.
MSF ERB approved the following process:
1. When researchers have decided what topic to
research in the next emergency, a “generic” research
protocol is submitted to the ERB for review and
pre-approval before the exact location is known.
2. Once the location is known, the final research
protocol must be submitted to local ethics
committee/authorities for approval.
3. At the same time, the final proposal is submitted to
the MSF ERB, including details pertinent to the
chosen location.
4. This review can be expedited by decision of the
chair. In this case, the chair plus two members will
pledge to provide a review and decision within
48 hours.
5. This decision can, however, be challenged by one or
more ERB members, leading to full ERB review. It is
expected that if this occurs, all members will provide
input within an additional 24 hours.
This process has been successfully used in assessing
the validity of new rapid diagnostic tests during a men-
ingitis outbreak with no reported harms to participants
and enhanced ability of researchers to respond in a timely
manner. Until recently this was the only instance in which
this process was used since it was agreed upon in 2008.
The procedure has, however, been applied to a qualitative
research protocol to understand local considerations and
practices related to Ebola Virus Disease (EVD).
Emergency ethics review was also discussed for research
to be carried out in the next Ebola fever outbreak. Previ-
ously, a review of research on filovirus haemorrhagic fever
outbreaks (Ebola/Marburg) published between 1999 and
2007, had shown that among 34 research interventions,
individual consent was sought in fifteen cases and ethics
review (international and local) was mentioned only in
three cases [17]. As MSF wished to carry out research on
supportive treatments in major outbreak settings, the ERB
suggested in 2010 a “generic” protocol be prepared, taking
into consideration how to involve potential victims (or
survivors) of these outbreaks in the development of such
protocols. As outbreaks are unpredictable in terms of tim-
ing and location, finding individuals at the time might be
unrealistic. However, some survivors are health workers
and it may be possible to involve them in protocol devel-
opment. In this specific case the “generic” research proto-
col could also be pre-approved by the relevant ethics
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Republic of Congo, Gabon, South Sudan, and Uganda.
This had not been taken forward by MSF before the re-
cent Ebola outbreak in West Africa. ERB members, MSF
medical directors and researchers met in October 2014,
and subsequent decisions to conduct clinical trials in the
Ebola outbreak were informed by the interaction of the
ERB and MSF. The virtual structure of the ERB provided
rapid and thorough expert review. It may also be note-
worthy that a number of the MSF ERB members have also
advised WHO on this issue.
General review of “routine surveys”
One major question has repeatedly been where to draw
the line between research and activities such as prospect-
ive disease prevalence surveys and rapid health assess-
ments. MSF routinely carries out vaccination coverage
surveys, nutritional surveys and retrospective mortality
surveys. These surveys and assessments often have to be
done in emergency settings for the purposes of program
planning and emergency response, and historically have
rarely been submitted to the ERB. Although these could
be considered low-risk surveys, the same survey may be
more sensitive in certain populations, such as a mortality
survey in Iraq or in Syrian refugees, mapping of water
quality in slums during the cholera epidemic in Haiti or
assessing access to health services for undocumented
migrants. Surveys cannot be presumed upfront to be
of minimal risk. Many sensitive and morally problem-
atic issues can be disclosed by surveys. Examples in-
clude discrimination or blaming of population groups,
psychological distress, dealing with uncovered child
abuse, or providing demographic characteristics of a
community that may enhance their attractiveness as
targets by combatants.
It was decided recently that the ERB should provide
guidance without reviewing every survey, adopting a simi-
lar approach to that related to the retrospective analysis of
routinely collected data. The ERB would trust researchers
to deliberate about potential risks and whether they
may want advice or review, within the following frame of
reference:
 Standard vaccination coverage, nutrition and
mortality survey instruments will be examined by
the ERB and review exemption granted under
certain conditions;
 Criteria for review exemption will be similar to
those for a posteriori analysis of routinely
collected data;
 Adding (or removing) a question from the
standard protocol means that it is not a standard
protocol anymore. Consequently an ERB review
will be needed. Sensitive survey research, such as sexual activity,
illegal behaviour or mental health, can never be
exempted from ethics review.
 As for a posteriori analysis of routinely collected
data, national or institutional ethical review in the
country from where the data originate may still be
required.
Implementation of this new policy will start in 2014,
including submission of generic survey protocols to the
ERB.
Looking at the impact of approved research
While Principle 34 of the Declaration of Helsinki [8]
only requests researchers to make provisions for post-
trial access for all participants who still need an inter-
vention identified as beneficial in the trial, the general
wording in principle 20 (“… this group should stand to
benefit from the knowledge, practices or interventions
that result from the research”), might be interpreted in
the sense of post-research access to a broader popula-
tion. The CIOMS guidelines (Guideline 10) emphasise
that “investigators must make every effort to ensure that
the research is responsive to the health needs and the
priorities of the population or community in which it is
to be carried out; and that any intervention or product
developed, or knowledge generated, will be made
reasonably available for the benefit of that population
or community” [9]. More recently, global actors have
highlighted the need to ensure that the outcomes and
benefits of publically-funded research are understood and
mapped, and that a strategic approach to harnessing re-
search results is taken by those seeking to improve health-
care delivery [18,19]. MSF as a global humanitarian actor
doing research clearly has to ensure that the benefits of
the research are made available to the study community.
However, the responsibility of MSF goes beyond respond-
ing to the health needs of the research population, using
positive results of research to improve policy and practice
at the national and international level [20].
The ERB has always closely examined the social value
of research, meaning its potential benefits for research
participants, the community and beyond during the re-
view process. To assess if claims made in research proto-
cols have translated into practice, the ERB requested
MSF for the first time in 2010 to report on the disse-
mination of research results and programmatic impact
of all research approved since the inception of the ERB.
We distinguish between impact in the literature (schol-
arly impact) and impact in the field of intervention.
Although examining impact in the literature may have
some value, one should not forget that what happens
after publication is what is important with operational
research and for organisations such as MSF. Changes in
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and real effects on programme performance (changes to
programme outcomes, decrease in morbidity and mor-
tality) are more relevant than scholarly impact.
Dissemination of research results was categorized as
(1) internal MSF report only, (2) limited sharing of
results at national or international level and (3) peer-
reviewed publication. The ERB received feedback on 234
protocols out of 248 reviewed between 2002 and 2013.
Overall 11 studies had been refused by the ERB and 38
protocols had to been cancelled after approval. 80 re-
search protocols were still ongoing at the end of 2013.
Of the remaining 105 studies, 76 lead to one or several
publications, 9 to a more limited dissemination of results
(i.e. poster or oral presentations), while the results of 20
studies were only shared internally through a report.
To assess impact at the programmatic and/or policy
level four broad categories were proposed: local project
impact, impact in the country where the study was done,
impact within MSF, (potential) changes on a global scale.
Given the fact that MSF research spans from oppor-
tunistic analyses of collected data to clinical trials, these
categories do not necessarily imply a hierarchy. Some
studies may be designed for local impact only; others
may from the outset have the ambition to change thera-
peutic protocols internationally [21]. In Figure 4 below,
each subsequent category encompasses the previous
one. For example, impact at national level includes
impact at the local level, and impact at a global scale
comprises impact on MSF operations. Table 3 provides
some examples for each of the four impact categories
[22-30].
The new framework explicitly asks for the dissemin-
ation strategy at community and global level, including
dissemination if the research findings are negative. In
addition, post-research obligations must be articulated at
the level of research participants, the community, others
in the same situation elsewhere, and should include an
(advocacy) plan in place to assure access to benefits of
the study results beyond MSF’s and MSF partners’ en-
gagement. Impact reporting has been systematised on anFigure 4 Estimated impact of all studies submitted to ERB
review and completed between 2002 and 2013.annual basis for all research protocols approved by the
ERB. It is important to note that this approach to impact
does not just follow orthodox approaches such as, for
example, citation counts. The ERB has also encouraged
MSF to share negative findings arising from MSF re-
search as well as positive findings. However, this has not
been explicitly assessed.
Summary
This paper shares the experience of an independently
functioning ethics review board serving a large medical
humanitarian organisation and shows how it has evolved
over time to face the growing challenges of research car-
ried out with vulnerable communities in resource- con-
strained or emergency settings. First and foremost, we
have noted over the years the importance of the dialogue
between MSF researchers and independent ERB mem-
bers. Continued interaction has allowed for progressive
innovations based on a trustful and respectful partner-
ship between the ERB and the researchers. During those
years we have learned to work together and to better
serve each other’s needs thus leading to a co-evolution
of researchers and the research ethics board. And most
importantly we have come to understand that research
ethics should be seen as an iterative evolving process.
Our experience shows that ethics review can be a con-
structive learning process, and a time of reflection and
critical debate. We think research ethics review should
take this format. This, of course, differs from the ordin-
ary perception of institutional ethics review as legalistic,
formulaic and at times obstructive.
While pursuing developments in various areas as
described in this paper in the coming years, we would
particularly like to focus our attention on three areas.
First, the impact of any new framework should be con-
tinuously assessed. While, in this case, we can already
sense after six months implementation, that it has been
adopted very easily and seems to be much more “intui-
tive” than the previous framework, a more rigorous
evaluation of its acceptance, implementation and impact
on the quality of research protocols would be useful not
only for MSF, but also for other organisations that are
facing the same challenges and might wish to adopt
and/or adapt it.
Second, the impact of research needs to be defined
more precisely to be meaningfully assessed. One must
also consider that impact changes over time - short,
medium and long term cumulative impact. The latency
of the impact may be shown in a meta-analysis or meta-
synthesis at a later time, or demonstrated by uptake of
the results into guidelines. It is impossible to predict up-
front when key impact will occur. Another important
question will be how sustainable changes implemented
based on research outcomes are over time.
Table 3 Examples of impact at various levels
Protocol title (date) Outcomes Publication
Global impact
Nifurtimox-eflornithine combination,
human African trypanosomiasis,
République du Congo (Clinical
equivalence study comparing the
nifurtimox-eflornithine combination with
the standard eflornithine regimen for the
treatment of Trypanosoma brucei
gambiense) (2003)
Combination treatment now standard in
MSF; stimulated DNDi to do the NECT study
published in 2009. (Priotto G et al. Nifurtimox-efl
ornithine combination therapy for second-stage
African Trypanosoma brucei gambiense
trypanosomiasis: a multicentre, randomized, phase III,
non-inferiority trial. Lancet 2009; 374:56-64.) This led
to change in WHO guidelines.
Priotto G et al. Nifurtimox-Eflornithine Combination
Therapy for Second-Stage Trypanosoma brucei
gambiense Sleeping Sickness: A Randomized
Clinical Trial in Congo. Clinical Infectious Diseases
2007; 45:1435–42.
Mental health treatment outcomes in
a humanitarian emergency. The
evaluation of a pilot model for the
integration of mental health into primary
care in Habilla, Darfur (2009)
Tremendous success in sharing mental health
tools among humanitarian actors
Souza R, Yasuda S, Cristofani S. Mental health
treatment outcomes in a humanitarian
emergency: a pilot model for the integration
of mental health into primary care in Habilla,
Darfur. Int J Ment Health Syst. 2009;3(1):17.
Tele-medicine/Tele-consultation - Does
this service improve health care delivery
in a remote conflict setting in Somalia?
(2011)
The introduction of telemedicine significantly
improved quality of paediatric care in a remote
conflict setting and showed that this technology
can be vital for training and capacity building. It
has led to the expansion and use of telemedicine
in similar settings. The study has also featured as a
case example in the WHO World Health Report
2013.
Zachariah R et al. Practicing medicine without
borders: tele-consultations and tele-mentoring
for improving paediatric care in a conflict setting
in Somalia? Tropical Medicine and International
Health 2012; 17(9) 1156–1162.
Impact within MSF programmes
Outcomes of a diabetic care program
in Cambodia: an observational cohort
study (2008)
Showed good blood sugar control could
be achieved in a low-resource setting. Model
of attaching chronic disease to HIV program
unique. May be a useful model for other MSF
programs looking at chronic diseases.
Raguenaud ME et al. Treating 4,000 diabetic
patients in Cambodia, a high-prevalence but
resource-limited setting: a 5-year study.
BMC Med. 2009;7:33. doi:10.1186/1741-7015-7-33.
Compliance and diagnostic profile
of referrals from Community Malaria
Volunteers to the MSF supported health
structures in Bo and Pujehun districts,
Sierra Leone (2009)
Highlighted low levels of community based
referral completions and its implications at
community level. Feeds into future operational
strategies related to use of community workers
in malaria care
Thomson A et al. Low referral completion of
rapid diagnostic test-negative patients in
community-based treatment of malaria in Sierra
Leone. Malaria Journal 2011;10:94.
Surgical site Infection after caesarean
section: A proxy for problems in
surgical care
Provided information on ways forward to improve
post-operative case and improve vigilance on
post-operative infection
Chu K et al. Caesarean section rates and
indications in sub-Saharan Africa: a multi-country
study from Médecins sans Frontières. PLoS One.
2012;7(9):e44484.
Impact at country level
Drug efficacy trial of three
artemisinin-based combination therapies:
Artesunate + Sulfadoxine-Pyrimethamine,
Artesunate + Amodiaquine and
Artemether + Lumefantrine (Coartem)
for the treatment of uncomplicated
Plasmodium falciparum malaria,
Republic of Congo (2004)
Led to artemisinin combination therapies
becoming the national malaria treatment policy
van den Broek I., Kitz C., Al Attas S., Libama F.,
Balasegaram M., Guthmann J-P. Efficacy of 3
artemisinin combination therapies for the
treatment of uncomplicated Plasmodium
falciparum malaria in the Republic of Congo.
Malar J 2006 Nov 24;5:113.
Assessing home based treatment
and care of MDR-TB patients in
northern Uganda (2011)
Findings used for advocacy report to push for
implementation of ambulatory treatment in
Uganda. Ambulatory model now part of national
protocol.
Poster: Casas EC et al. A decentralized community-
based MDR-TB model of care in northern Uganda.
MSF-UK Scientific Day, 25 May 2012, London, U.K
and 43rd Union World Conference on Lung Health.
Local level impact
Reasons why women default from
a prevention of mother to child
transmission of HIV (PMTCT) program
and views of men on PMTCT activities
in the informal settlement of
Kibera, Nairobi, Kenya (2007)
Helped to generate knowledge on factors
associated with default and re-orient the
existing programs to improve community
acceptability
Kizito KW et al. Lost to follow up from tuberculosis
treatment in an urban informal settlement (Kibera),
Nairobi, Kenya: what are the rates and determinants?
Trans R Soc Trop Med Hyg 2011; 105: 52-57.
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Table 3 Examples of impact at various levels (Continued)
A case study of a collaborative
initiative between an HIV/AIDS Clinic
and a Community Non-Governmental
Organization Network in Mumbai,
India (2010)
The Mumbai team learned an important lesson
regarding followup of defaulters: not to
approach the homes, but to contact by other
means. To avoid stigma.
Errol L et al. Tracing patients on antiretroviral
treatment lost-to-follow-up in an urban slum in
India. J Adv Nurs 2012; 68(11); 2399-409.
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ethics committees in the study countries should be en-
hanced [31]. Until now this relationship has been limited
to seeing each other’s approvals and sometimes the full
comments. A more structured and continuous exchange
could, for example, be initiated with national ethics
committees in countries where MSF has been present
a long time and is repeatedly carrying out research
activities.
We hope that the innovations in research ethics gov-
ernance described in this paper may be relevant for
other organisations carrying out research in fragile con-
texts and for ethics committees reviewing such research.Endnotes
aFull review requiring participation of all ERB mem-
bers, is warranted if the effectiveness, efficacy or safety
of a given procedure or therapy is tested on human sub-
jects and/or if the research involves collecting body/tis-
sue samples with hypothesis testing (e.g. all clinical trials
and some operational research projects). Expedited re-
view, requiring participation of two or three ERB mem-
bers, is deemed sufficient if the research carries only
minimal risks to human subjects.
bA research ethics framework for similar contexts was
produced by R2HC [32] after we had revised our frame-
work. It will take us too far from the purpose of this
paper to offer any detailed comparative analysis but it
should be noted that the RCHC framework largely sum-
marizes existing literature and follows our revised frame-
work in many respects.
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